# A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

> **NCT03099187** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 253 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03099187
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2018-11-21
- **Final completion:** 2020-01-10
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099187, "A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03099187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*